Income StatementBalance SheetCash FlowSegments
Roivant Sciences logo

Roivant Sciences Business Segments

Business, geographic, and product segment breakdowns

Roivant Sciences generates $8.3M in annual revenue across 3 key segments: Bermuda (-), Switzerland ($79.9M), and United States ($53.5M). Based on the Q1 2026 filing.

Bermuda (TTM)-Switzerland (TTM)$79.9MUnited States (TTM)$53.5M
Latest FilingQ1 2026
Report Date2026-05-20
Market Cap$21.6B

Products & Services

Research and development (includes $47,867, $39,780 and $32,400 of share-based compensation expense for the years ended March 31, 2026, 2025 and 2024, respectively)

SegmentQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Anti-FcRn franchise—contractual costs related to batoclimab program discontinuation$0.0$0.0$9.7M$9.7M$9.7M$9.7M

Research and development (includes $18,123and $9,685 of share-based compensation expense for the three months ended December 31, 2025 and 2024 and $40,218and $30,128 for the nine months ended December 31, 2025 and 2024, respectively)

SegmentQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Anti-FcRn franchise—endocrine diseases$15.5M$16.8M$19.3M$24.9M$19.8M$26.3M
Anti-FcRn franchise—neurological diseases$25.0M$20.2M$20.9M$23.1M$17.7M$20.8M
Brepocitinib$10.9M$13.1M$15.0M$14.7M$16.2M$14.3M
Other development and discovery programs$14.6M$14.0M$10.2M$11.2M$13.4M$13.4M
Anti-FcRn franchise—rheumatology diseases$8.2M$6.7M$8.2M$13.6M$14.1M$12.9M
Mosliciguat$4.7M$5.9M$8.4M$7.5M$10.4M$9.8M
Anti-FcRn franchise—dermatology diseases$5.0M$5.7M$5.1M$8.0M$3.0M$4.1M
Anti-FcRn franchise—other clinical and nonclinical$44.0K$1.7M$2.4M$319.0K$463.0K$193.0K

Geographic

Total current tax expense

SegmentQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Switzerland$0.0$0.0$20.0M$20.0M$20.0M$20.0M
United States$12.0M$12.0M$13.4M$13.4M$13.4M$13.4M
Bermuda$0.0$0.0$0.0$0.0$0.0$0.0

Total deferred tax benefit

SegmentQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Bermuda$0.0$0.0$0.0$0.0$0.0$0.0
Switzerland$0.0$0.0$0.0$0.0$0.0$0.0
United States$0.0$0.0$0.0$0.0$0.0$0.0

Total (loss) income from continuing operations before income taxes

SegmentQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
United States-4369075000.0%-4369075000.0%-8862725000.0%-8862725000.0%-8862725000.0%-8862725000.0%
Bermuda-2014750000.0%-2014750000.0%1559150000.0%1559150000.0%1559150000.0%1559150000.0%
Switzerland-10661950000.0%-10661950000.0%542775000.0%542775000.0%542775000.0%542775000.0%

Current Income Tax Expense Benefit

SegmentQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Other$0.0$0.0-$6.8K-$6.8K-$6.8K-$6.8K

Deferred Tax

SegmentQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Other$0.0$0.0$0.0$0.0$0.0$0.0

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

SegmentQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Other6025000.0%6025000.0%146350000.0%146350000.0%146350000.0%146350000.0%

Net operating losses

SegmentQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Switzerland—$2.6B———$1.5B
United States—$223.3M———$890.7M
United Kingdom—$342.0M———$613.4M

Tax Credit Carryforward Amount

SegmentQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
States in U.S and Canada—$7.0M———$10.8M

Annual net operating loss utilization limitation percentage

SegmentQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
United States20.0%20.0%20.0%20.0%20.0%20.0%

Federal research tax credit carryforwards

SegmentQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
United States—$47.1M———$66.0M

Business Segments

MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Gain on litigation settlement$0.0$0.0$192.6M$192.6M$192.6M$192.6M
Income tax expense (benefit)-$25.6M$49.3M$4.6M$7.0M$23.3M$98.4M
Share-based compensation$69.4M$73.8M$71.1M$70.8M$86.9M$69.5M
General and administrative (includes $86,874 and $69,386 of share-based compensation expense for the three months ended December 31, 2025 and 2024 and $228,778 and $165,670 for the nine months ended December 31, 2025 and 2024, respectively)$38.6M$32.7M$29.2M$38.0M$60.0M$49.2M
Research and development (includes $18,123and $9,685 of share-based compensation expense for the three months ended December 31, 2025 and 2024 and $40,218and $30,128 for the nine months ended December 31, 2025 and 2024, respectively)$38.3M$42.7M$42.5M$40.7M$41.4M$43.2M
Investment Income, Interest$61.9M$54.6M$48.3M$45.3M$43.3M$41.2M
Other Nonoperating Income (Expense)-$2.8M-$2.8M—-$5.7M$8.3M$12.6M
Gain on deconsolidation$777.0K$777.0K$2.8M$2.8M$2.8M$2.8M
Revenue$9.0M$7.6M$2.2M$1.6M$2.0M$2.5M
Cost of revenues$259.0K$205.0K$154.0K$111.0K$700.0K$320.0K
Acquired in-process research and development$0.0$0.0$0.0$0.0$0.0$0.0
Gain (loss) on fair value of liability instruments$2.1M$14.1M—-$21.0M-$24.4M—
Gain (Loss) on Investments-$21.3M$12.9M—$128.5M$21.6M—
Gain on sale of Telavant net assets$0.0—$0.0$0.0$0.0$0.0
Income from discontinued operations, net of tax$327.0M—$0.0$0.0$0.0$0.0
Net (loss) income$118.1M-$252.4M—-$166.0M-$313.7M—